NOT FOR DISTRIBUTION
Header cover image

Market Cap

CHF46.0m

Last Updated

2021/04/19 17:15 UTC

Data Sources

Company Financials +

Executive Summary

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. More Details


Snowflake Analysis

Exceptional growth potential and fair value.

Share Price & News

How has Newron Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NWRN is more volatile than 90% of Swiss stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: NWRN's weekly volatility has decreased from 16% to 8% over the past year, but is still higher than 75% of Swiss stocks.


Market Performance


7 Day Return

-6.9%

NWRN

0.05%

CH Pharmaceuticals

1.8%

CH Market


1 Year Return

-61.0%

NWRN

-5.5%

CH Pharmaceuticals

35.7%

CH Market

Return vs Industry: NWRN underperformed the Swiss Pharmaceuticals industry which returned -5.5% over the past year.

Return vs Market: NWRN underperformed the Swiss Market which returned 35.7% over the past year.


Shareholder returns

NWRNIndustryMarket
7 Day-6.9%0.05%1.8%
30 Day-16.6%0.9%4.0%
90 Day-9.7%-3.0%9.2%
1 Year-61.0%-61.0%-2.4%-5.5%40.2%35.7%
3 Year-76.7%-76.7%42.4%22.8%37.9%22.9%
5 Year-86.4%-86.4%41.3%14.6%70.7%39.8%

Long-Term Price Volatility Vs. Market

How volatile is Newron Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Newron Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: NWRN (CHF2.42) is trading below our estimate of fair value (CHF102.06)

Significantly Below Fair Value: NWRN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: NWRN is unprofitable, so we can't compare its PE Ratio to the XE Pharmaceuticals industry average.

PE vs Market: NWRN is unprofitable, so we can't compare its PE Ratio to the Swiss market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NWRN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NWRN is good value based on its PB Ratio (2.3x) compared to the CH Pharmaceuticals industry average (3.3x).


Future Growth

How is Newron Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

48.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NWRN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.3%).

Earnings vs Market: NWRN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: NWRN's is expected to become profitable in the next 3 years.

Revenue vs Market: NWRN's revenue (40.4% per year) is forecast to grow faster than the Swiss market (4.6% per year).

High Growth Revenue: NWRN's revenue (40.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NWRN's Return on Equity is forecast to be very high in 3 years time (209%).


Past Performance

How has Newron Pharmaceuticals performed over the past 5 years?

-2.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NWRN is currently unprofitable.

Growing Profit Margin: NWRN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NWRN is unprofitable, and losses have increased over the past 5 years at a rate of 2.5% per year.

Accelerating Growth: Unable to compare NWRN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NWRN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.3%).


Return on Equity

High ROE: NWRN has a negative Return on Equity (-121.76%), as it is currently unprofitable.


Financial Health

How is Newron Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: NWRN's short term assets (€37.9M) exceed its short term liabilities (€6.9M).

Long Term Liabilities: NWRN's short term assets (€37.9M) exceed its long term liabilities (€27.1M).


Debt to Equity History and Analysis

Debt Level: NWRN's debt to equity ratio (148.9%) is considered high.

Reducing Debt: NWRN's debt to equity ratio has increased from 2% to 148.9% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NWRN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if NWRN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Newron Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NWRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NWRN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NWRN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NWRN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NWRN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.8yrs

Average management tenure


CEO

Stefan Weber (55 yo)

8.83yrs

Tenure

€582,000

Compensation

Mr. Stefan Weber serves as the Chief Financial Officer and Finances and Administration Director at Duktus S.A. Mr. Weber has been the Chief Executive Officer of Newron Pharmaceuticals SpA since June 1, 201...


CEO Compensation Analysis

Compensation vs Market: Stefan's total compensation ($USD700.11K) is above average for companies of similar size in the Swiss market ($USD482.53K).

Compensation vs Earnings: Stefan's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: NWRN's management team is seasoned and experienced (8.8 years average tenure).


Board Members

Experienced Board: NWRN's board of directors are considered experienced (9.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Newron Pharmaceuticals S.p.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Newron Pharmaceuticals S.p.A.
  • Ticker: NWRN
  • Exchange: SWX
  • Founded: 1999
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CHF46.041m
  • Shares outstanding: 17.85m
  • Website: https://www.newron.com

Number of Employees


Location

  • Newron Pharmaceuticals S.p.A.
  • Via Antonio Meucci 3
  • Bresso
  • Milan
  • 20091
  • Italy

Listings


Biography

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral ne...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/19 17:15
End of Day Share Price2021/04/19 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.